Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOBEEN H RATHORE

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1245299320
CMS profile
101360
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$65.02

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $65.02 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Becton, Dickinson and Company $40.89 1
ABBVIE INC. $24.13 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOBEEN H RATHORE

NPI 1245299320 · CMS profile ID 101360

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245299320?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOBEEN H RATHORE, NPI 1245299320, CMS profile ID 101360. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245299320?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MOBEEN H RATHORE, NPI 1245299320, CMS profile ID 101360. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245299320?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MOBEEN H RATHORE, NPI 1245299320, CMS profile ID 101360, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1245299320?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $65.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Becton, Dickinson and Company $40.8912/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232253718 CMS
ABBVIE INC. $24.1311/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203785042 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,866.71 2
PY2021 $8,670.00 3
PY2022 $7,102.52 10
PY2023 $7,023.35 11
PY2024 $2,000.00 1
PY2025 $65.02 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $137,102.80 37
PY2024 Recipient $669.58 2
PY2024 Principal investigator $96,258.25 30
PY2023 Principal investigator $434,794.19 88
PY2022 Principal investigator $1,042,249.00 59
PY2021 Principal investigator $243,963.73 16
PY2020 Recipient $649.69 1
PY2020 Principal investigator $11,740.58 12
PY2019 Principal investigator $23,459.64 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $72.74 12/31/2023 Non-covered Recipient Entity
Baptist Medical Center,Wolfson Childrens Hospital
A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozone,Tazobactam MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Subjects with Complicated Intra-Abdominal Infections No dispute reported 06/30/2026 1042547139
Principal investigator 1 ModernaTX, Inc. $4,420.00 12/19/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042042189
Principal investigator 1 ModernaTX, Inc. $520.00 12/19/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Double-Blind, Randomized, Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214SARS-CoV-2 Vaccine in Healthy Babies aged 0 to 6 months. No dispute reported 06/30/2026 1042042207
Principal investigator 1 ModernaTX, Inc. $400.00 12/14/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042042195
Principal investigator 1 ModernaTX, Inc. $19,305.00 12/14/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042042201
Principal investigator 1 ModernaTX, Inc. $117.00 12/12/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042042183
Principal investigator 1 ModernaTX, Inc. $1,061.12 12/07/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042042177
Principal investigator 1 ModernaTX, Inc. $400.00 11/21/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042042147
Principal investigator 1 ModernaTX, Inc. $650.00 11/14/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042042137
Principal investigator 1 ModernaTX, Inc. $1,040.00 11/09/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Double-Blind, Randomized, Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214SARS-CoV-2 Vaccine in Healthy Babies aged 0 to 6 months. No dispute reported 06/30/2026 1042042153
Principal investigator 1 ModernaTX, Inc. $390.00 11/02/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042042141
Principal investigator 1 Hoffmann-La Roche Limited $3,640.00 10/19/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040584529
Principal investigator 1 ModernaTX, Inc. $2,279.68 10/17/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042042069
Principal investigator 1 ModernaTX, Inc. $1,261.00 10/12/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042042057
Principal investigator 1 ModernaTX, Inc. $1,170.00 10/10/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042042063
Principal investigator 1 ModernaTX, Inc. $1,040.00 10/10/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042042075
Principal investigator 1 ModernaTX, Inc. $520.00 10/02/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1042042023
Principal investigator 1 ModernaTX, Inc. $20,845.50 10/02/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1042042029
Principal investigator 1 ModernaTX, Inc. $1,454.70 10/02/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1042042037
Principal investigator 1 ModernaTX, Inc. $2,860.00 10/02/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1042042043
Principal investigator 1 ModernaTX, Inc. $800.00 09/19/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041935
Principal investigator 1 ModernaTX, Inc. $400.00 09/19/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041941
Principal investigator 1 ModernaTX, Inc. $800.00 09/14/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041947
Principal investigator 1 ModernaTX, Inc. $800.00 09/14/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041951
Principal investigator 1 Merck Sharp & Dohme LLC $455.40 09/12/2023 Non-covered Recipient Entity
University of Florida Jacksonville NICHD CRS
STUDY NAME#IMPAACT P1115, Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission# A Phase I,II Proof of Concept Study No dispute reported 06/30/2026 1042489777
Principal investigator 1 ModernaTX, Inc. $14.82 09/12/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041929
Principal investigator 1 ModernaTX, Inc. $4,318.18 09/12/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041959
Principal investigator 1 ModernaTX, Inc. $1,040.00 09/12/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041965
Principal investigator 1 ModernaTX, Inc. $3,608.80 09/05/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Study to Evaluate the Safety and Immunogenicity of the mRNA-1273.214 COVID-19 Vaccine in Healthy Children Between 6 Months to Less Than 6 Years of Age No dispute reported 06/30/2026 1042041971
Principal investigator 1 ModernaTX, Inc. $260.00 09/01/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1042041977
Principal investigator 1 ModernaTX, Inc. $650.00 08/24/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1042042117
Principal investigator 1 ModernaTX, Inc. $650.00 08/22/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1042042391
Principal investigator 1 Hoffmann-La Roche Limited $3,900.00 08/15/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040584471
Principal investigator 1 Hoffmann-La Roche Limited $14,950.00 08/15/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040584485
Principal investigator 1 Hoffmann-La Roche Limited $520.00 08/15/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040584501
Principal investigator 1 Hoffmann-La Roche Limited $7,800.00 08/15/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040584515
Principal investigator 1 ModernaTX, Inc. $874.38 08/10/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041859
Principal investigator 1 ModernaTX, Inc. $520.00 08/10/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1042042125
Principal investigator 1 Hoffmann-La Roche Limited $2,990.00 08/08/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040584441
Principal investigator 1 Hoffmann-La Roche Limited $5,200.00 08/08/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040584457
Principal investigator 1 ModernaTX, Inc. $1,040.00 08/08/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041903
Principal investigator 1 ModernaTX, Inc. $469.30 08/03/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041841
Principal investigator 1 ModernaTX, Inc. $325.00 08/03/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041847
Principal investigator 1 ModernaTX, Inc. $1,950.00 08/03/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041865
Principal investigator 1 ModernaTX, Inc. $14,239.81 08/01/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041853
Principal investigator 1 ModernaTX, Inc. $800.00 08/01/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041871
Principal investigator 1 ModernaTX, Inc. $5,640.70 07/20/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041883
Principal investigator 1 ModernaTX, Inc. $1,040.00 07/20/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041891
Principal investigator 1 ModernaTX, Inc. $520.00 07/20/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041897
Principal investigator 1 ModernaTX, Inc. $650.00 07/20/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1042042235
Principal investigator 1 ModernaTX, Inc. $1,560.00 07/05/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1042042111
Principal investigator 1 ModernaTX, Inc. $2,000.00 06/22/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041829
Principal investigator 1 ModernaTX, Inc. $800.00 06/22/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041835
Principal investigator 1 ModernaTX, Inc. $44,897.52 06/20/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041823
Principal investigator 1 ModernaTX, Inc. $1,560.00 06/20/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041877
Principal investigator 1 ModernaTX, Inc. $520.00 06/20/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1042042105
Principal investigator 1 ModernaTX, Inc. $19,500.00 06/15/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1042041909
Principal investigator 1 ModernaTX, Inc. $18,878.01 06/13/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041815
Principal investigator 1 ModernaTX, Inc. $1,300.00 06/08/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1042042093
Principal investigator 1 ModernaTX, Inc. $1,300.00 06/06/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1042041917
Principal investigator 1 ModernaTX, Inc. $2,600.00 06/06/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1042041923
Principal investigator 1 ModernaTX, Inc. $2,600.00 06/01/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1042042099
Principal investigator 1 ModernaTX, Inc. $520.00 05/18/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041795
Principal investigator 1 ModernaTX, Inc. $1,040.00 05/18/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041803
Principal investigator 1 ModernaTX, Inc. $520.00 05/18/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041809
Principal investigator 1 ModernaTX, Inc. $4,289.15 05/02/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041789
Principal investigator 1 ModernaTX, Inc. $19,500.00 05/02/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1042042087
Principal investigator 1 ModernaTX, Inc. $3,395.02 04/20/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041781
Principal investigator 1 ModernaTX, Inc. $20.40 04/07/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1041799047
Principal investigator 1 ModernaTX, Inc. $42.50 04/05/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1041799039
Principal investigator 1 ModernaTX, Inc. $1,585.45 04/03/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041757
Principal investigator 1 ModernaTX, Inc. $2,600.00 03/28/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041769
Principal investigator 1 ModernaTX, Inc. $1,300.00 03/28/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041775
Principal investigator 1 ModernaTX, Inc. $2,800.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041751
Principal investigator 1 ModernaTX, Inc. $1,256.00 03/21/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041745
Principal investigator 1 ModernaTX, Inc. $5,691.72 03/14/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041739
Principal investigator 1 ModernaTX, Inc. $103,399.20 03/02/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041733
Principal investigator 1 ModernaTX, Inc. $15,504.38 02/23/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041721
Principal investigator 1 ModernaTX, Inc. $400.00 02/23/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041727
Principal investigator 1 ModernaTX, Inc. $290.23 02/14/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041715
Principal investigator 1 ModernaTX, Inc. $325.00 02/07/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041709
Principal investigator 1 ModernaTX, Inc. $16,035.50 02/01/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042041763
Principal investigator 1 ModernaTX, Inc. $5,230.23 01/17/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041703
Principal investigator 1 ModernaTX, Inc. $4,000.00 01/12/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041685
Principal investigator 1 ModernaTX, Inc. $195.00 01/12/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041691
Principal investigator 1 ModernaTX, Inc. $65.00 01/12/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041697
Principal investigator 1 ModernaTX, Inc. $650.00 01/12/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042042231
Principal investigator 1 ModernaTX, Inc. $5,950.75 01/10/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042041679